leadf
logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement

SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with Winclove Probiotics which is well ahead of schedule. Ashman adds that their work with partner Croda to develop an active skincare ingredient is also making good progress.

Quick facts: SkinBioTherapeutics PLC

Price: 16.375 GBX

AIM:SBTX
Market: AIM
Market Cap: £25.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

SkinBioTherapeutics raise £4m to expand SkinBiotix technology in oral and...

Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications. Quinn explains how they plan to expand skin biotics technology into oral and healthcare as...

on 14/10/20

2 min read